MET and hepatocellular carcinoma: As revealed in our previous work [33], c-MET high signature in combination with PTEN loss of function mutation also predicted poor prognosis of HCC patients and showed sensitivity to FASN inhibitors rather than tyrosine kinase inhibitors.